Marshall Edwards (MSHL) Appoints Thomas Zech as CFO; Other Changes Announced
Novogen Limited's subsidiary, Marshall Edwards, Inc. (NASDAQ: MSHL), has announced today the appointment of Mr. Thomas Zech as its CFO and Company Secretary based in San Diego. This follows the appointment of Dr. Daniel Gold as CEO of Marshall Edwards, Inc. in April 2010 and is part of the continuing strategy to focus the Group's resources towards oncology drug research and development.
Following these appointments Novogen has restructured its Australian management team and has appointed Mr. Mark Hinze as CFO and Operations Manager of Novogen. Mr. Hinze has been with the Novogen Group for over 10 years and previously held the position of the Group's Financial Controller.
Mr. David Seaton, who was previously CFO of Novogen and CFO and Company Secretary of Marshall Edwards, Inc., and more recently Acting CEO, will leave the Company today. Also, due to the high priority of current and future clinical programs now being managed from the US, Novogen's Group Director of Research Professor Alan Husband will leave the Group at the end of June 2010.
A number of other management changes will also take effect from the end of June as part of the restructure.
In the meantime, Novogen staff will continue to work closely with Marshall Edwards in developing the Group's cancer compounds, and will continue to provide Marshall Edwards with administration and technical services. In addition, Novogen will continue to seek opportunities to develop its Glucan technology and to maximize shareholder value from its Consumer Health Care business.
Create E-mail AlertRelated Categories
Management ChangesStocks Mentioned
-0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
